7.00 - 7.25 - Registration and Continental Breakfast

7.25 - 7.30 - Introductory Remarks

7.30 - 9.30 - Management of Pancreatobiliary Malignancies

Points of Discussion:

• Surgery in the management of patients with pancreatic cancer
  • Identifying patients who would benefit
  • Expected benefits and potential risks
  • Palliative surgery – is there any role now?
• Surgery in the management of patients with bile duct cancer
  • Surgical options- resection vs transplant
  • Identifying patients who would benefit
  • Expected benefits
• Role of chemotherapy ± radiation in management of patients with pancreatic and bile duct cancers
  • Resectable vs borderline resectable vs unresectable tumors
  • Expected benefits
  • Radiotherapy for unresectable pancreatic cancer - role
• EUS and ERCP in the management of pancreatic cancer how recent advances can potentially help improve outcomes

9.30 - 9.45 - Coffee Break

9.45 - 11.15 - Minimally Invasive Procedures for Management of Gastrointestinal Cancers

1. Radiofrequency ablation for Barrett’s esophagus with HGD – Gregory Ginsberg
2. Transanal endoscopic microsurgery - Dana Sands
3. Minimally invasive esophagectomy - James Luketich
4. Endoscopic stent placement - Todd Baron
5. Laparoscopic pancreatectomy - Atilla Nakeeb

11.15 - 12.15 - Physicians and the Law

12.15-1.15 - Lunch

1.15 - 2.45 - Early Diagnosis of Pancreatic Cancer

Points of Discussion:

• Are there enriched patient subgroups in whom testing for pancreatic cancer may be useful?
• Patients with genetic predisposition to pancreatic cancer- is early diagnosis possible in these patients with screening /surveillance programs?
• Serum markers for pancreatic cancer- Are they realistic or just wishful thinking?
• Does the advent of EUS make the screening/surveillance for pancreatic cancer more meaningful?

2.45 - 3.15 - State of the Art Lecture – Advances in Nuclear Medicine and its Impact on Diagnosis and Management of GI Cancers

3.15 - 3.30 - Coffee Break  

3.30 - 5.00 - Post-Treatment Follow-up and Management of Recurrent GI Cancers

Intensive post-treatment; is it beneficial and worth the cost in patients with colorectal cancers?

Post-treatment surveillance in patients with esophageal cancer; is it beneficial and worth the cost?

5.00 pm Conference Adjourned